CPRX
Research Snapshot
Static fundamentals, valuation context, and investor signals for CATALYST PHARMACEUTICALS, INC. (CPRX).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
22.5%
ROIC, 35.4% FCF margin
Growth
37.7%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 6.1x current ratio
Superinvestors
2
Top: Third Avenue Management (0.8%)
Strengths to research
- Revenue compounded at 37.7% over five years.
- Free cash flow compounded at 35.9% over five years.
- Return on equity is strong at 22.5%.
- Free cash flow margin is healthy at 35.4%.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for CPRX.
Grade D
45
/ 100
Financial Charts
No financial data available for CPRX (annual).
2 superinvestors own CPRX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Terry Smith Fundsmith | 844,887 | $21M | 0.16% | 0.0% |
| Third Avenue Management Third Avenue Management | 210,161 | $5M | 0.84% | 0.0% |